Exchange Alley was in a fever of excitement. The Company's stock, which had been at a hundred and thirty the previous day, gradually rose to three hundred, and continued to rise with the most astonishing rapidity during the whole time that the bill in its several stages was under discussion. Mr. Walpole was almost the only statesman in the House who spoke out boldly against it. He warned them, in eloquent and solemn language, of the evils that would ensue. It countenanced, he said, "the dangerous practice of stockjobbing, and would divert the genius of the nation from trade and industry. It would hold out a dangerous lure to decoy the unwary to their ruin, by making them part with the earnings of their labour for a prospect of imaginary wealth." The great principle of the project was an evil of first-rate magnitude; it was to raise artificially the value of the stock, by exciting and keeping up a general infatuation, and by promising dividends out of funds which could never be adequate to the purpose. In a prophetic spirit he added, that if the plan succeeded, the directors would become masters of the government, form a new and absolute aristocracy in the kingdom, and control the resolutions of the legislature. If it failed, which he was convinced it would, the result would bring general discontent and ruin upon the country. Such would be the delusion, that when the evil day came, as come it would, the people would start up, as from a dream, and ask themselves if these things could have been true. All his eloquence was in vain. He was looked upon as a false prophet, or compared to the hoarse raven, croaking omens of evil. His friends, however, compared him to Cassandra, predicting evils which would only be believed when they came home to men's hearths, and stared them in the face at their own boards. Although, in former times, the House had listened with the utmost attention to every word that fell from his lips, the benches became deserted when it was known that he would speak on the South Sea question.The bill was two months in its progress through the House of Commons. During this time every exertion was made by the directors and their friends, and more especially by the Chairman, the noted Sir John Blunt, to raise the price of the stock. The most extravagant rumours were in circulation. Treaties between England and Spain were spoken of, whereby the latter was to grant a free trade to all her colonies; and the rich produce of the mines of Potosi-la-Paz was to be brought to England until silver should become almost as plentiful as iron. For cotton and woollen goods, with which we could supply them in abundance, the dwellers in Mexico were to empty their golden mines. The company of merchants trading to the South Seas would be the richest the world ever saw, and every hundred pounds invested in it would produce hundreds per annum to the stockholder. At last the stock was raised by these means to near four hundred; but, after fluctuating a good deal, settled at three hundred and thirty, at which price it remained when the bill passed the Commons by a majority of 172 against 55.…It seemed at that time as if the whole nation had turned stockjobbers. Exchange Alley was every day blocked up by crowds, and Cornhill was impassable for the number of carriages. Everybody came to purchase stock. "Every fool aspired to be a knave." In the words of a ballad, published at the time, and sung about the streets, "A South Sea Ballad; or, Merry Remarks upon Exchange Alley Bubbles. To a new tune, called 'The Grand Elixir; or, the Philosopher's Stone Discovered.'"
Comments, observations and thoughts from two bloggers on applied statistics, higher education and epidemiology. Joseph is an associate professor. Mark is a professional statistician and former math teacher.
Wednesday, March 31, 2021
"Every fool aspired to be a knave"
Tuesday, March 30, 2021
Even if scoundrels and fools get huge returns, that doesn't mean the reasons for avoiding scoundrels and fools no longer apply
This well-written paragraph, from @RobinWigg article in the @FT on " #Archegos poses hard questions for #WallStreet", captures well the fallacy of composition issue that I've seen play out repeatedly in finance, and that risks fueling disorderly de-leveraging and distressed sales pic.twitter.com/EIaX8JzBnc
— Mohamed A. El-Erian (@elerianm) March 29, 2021
"Concerns about his reputation and history were offset by a sense of the huge opportunities from dealing with him, according to two of Archegos’s prime brokers. He is known as an “aggressive, moneymaking genius”, according to one analyst note.https://t.co/xrBRYzNXA7
— JC Oviedo (@JCOviedo6) March 29, 2021
This is way out of my field, but you'd think that in a time of SPACs, billion dollar unicorns that lose money on every transaction but hope to make it up in volume, meme stocks, insane volatility, investor cults of personality and P/Es over a thousand, putting aside concerns might be a bad idea.
From Bloomberg:
Bill Hwang, a former hedge fund manager who’d pleaded guilty to insider trading, was deemed such a risk by Goldman Sachs Group Inc. that as recently as late 2018 the firm refused to do business with him.
Those misgivings didn’t last.
Wall Street’s premier investment bank, lured by the tens of millions of dollars a year in commissions that a whale like Hwang paid to rival dealers, removed his name from its blacklist and allowed him to become a major client. Just as Morgan Stanley, Credit Suisse Group AG and others did, Goldman fueled a pipeline of billions of dollars in credit for Hwang to make highly leveraged bets on stocks such as Chinese tech giant Baidu Inc. and media conglomerate ViacomCBS Inc.
Now Hwang is at the center of one of the greatest margin calls of all time, his giant portfolio in a messy and painful liquidation, and Goldman’s reversal has thrust it right into the mayhem.
Monday, March 29, 2021
Vitamin D
Friday, March 26, 2021
AstraZeneca dust-up
This is Joseph
Statement from AstraZeneca was titled (emphasis mine):
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
Gave results of:
79% vaccine efficacy at preventing symptomatic COVID-19
100% efficacy against severe or critical disease and hospitalisation
Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over
Statement from NIAID:
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.
Full results from AstraZeneca:
76% vaccine efficacy against symptomatic COVID-19
100% efficacy against severe or critical disease and hospitalisation
85% efficacy against symptomatic COVID-19 in participants aged 65 years and over
So a few points. One, the data was from the interim analysis, even though it was definitely out of date at the time of publication. Still, it was one of two reportable numbers. Noah Haber discusses this here, including noting that the protocol is publicly available.
Two, the media framing looks terrible. Unless the results are misreported, the interim analysis was 3% high in the overall and 5% low in the over 65 participants. These are small changes and kind of average out, given that efficacy in over 65 year old participants was a concern because of under-participation in the earlier AstraZeneca trials. But this framing seems excessive:
Federal officials were taken aback by the board’s allegations. One said the way that AstraZeneca handled the results was the equivalent of “telling your mother you got an A in a course, when you got an A in the first quiz but a C in the overall course.” Another said the disclosure by the board would inevitably hurt the company’s credibility with U.S. regulators.
I am not sure I would consider the two reports materially different. Certainly, I do not see them as being the difference between an A and C (probably I would call them both B's, compared to other trials and the degree of change between them). Since they were doing frequentist statistics, looking at numbers between the two prespecified analyses seems like a bad plan (p-hacking concerns arise). That said, why is the analysis plan not Bayesian?
That said, unless these numbers are false in some way, how is this a major change?
Finally, why doesn't the United States just give up on approving AstraZeneca and agree to allow it to be exported. It is pretty clear that US regulators have decided that they aren't interested in the product but the export restriction is blocking shipping it to other places that could actually use it. Why not be honest, say they won't need it (they don't) and allow it to be exported to other places across the globe who are desperate for vaccines. Isn't it in everybody's best interests to reduce variants by increasing resistance to covid-19 infections globally?
How is this the best plan?
Thursday, March 25, 2021
Repost: I wonder where Republicans got the idea that they could get away with using false claims about election fraud to justify voter suppression
TUESDAY, MAY 3, 2016
Context only counts if it shows up in the first two dozen paragraphs
In the third paragraph, we have two conflicting claims that go to the foundation of the whole debate. If election fraud is a significant problem, you can make a case for voter ID laws. If not, it's difficult to see this as anything other than voter suppression. This paragraph pretty much demands some additional information to help the reader weigh the claims and the article provides it...
Stricter Rules for Voter IDs Reshape Races
By MICHAEL WINES and MANNY FERNANDEZ MAY 1, 2016
SAN ANTONIO — In a state where everything is big, the 23rd Congressional District that hugs the border with Mexico is a monster: eight and a half hours by car across a stretch of land bigger than any state east of the Mississippi. In 2014, Representative Pete Gallego logged more than 70,000 miles there in his white Chevy Tahoe, campaigning for re-election to the House — and lost by a bare 2,422 votes.
So in his bid this year to retake the seat, Mr. Gallego, a Democrat, has made a crucial adjustment to his strategy. “We’re asking people if they have a driver’s license,” he said. “We’re having those basic conversations about IDs at the front end, right at our first meeting with voters.”
Since their inception a decade ago, voter identification laws have been the focus of fierce political and social debate. Proponents, largely Republican, argue that the regulations are essential tools to combat election fraud, while critics contend that they are mainly intended to suppress turnout of Democratic-leaning constituencies like minorities and students.
More than twenty paragraphs later.
Mr. Abbott, perhaps the law’s most ardent backer, has said that voter fraud “abounds” in Texas. A review of some 120 fraud charges in Texas between 2000 and 2015, about eight cases a year, turned up instances of buying votes and setting up fake residences to vote. Critics of the law note that no more than three or four infractions would have been prevented by the voter ID law.
Nationally, fraud that could be stopped by IDs is almost nonexistent, said Lorraine C. Minnite, author of the 2010 book “The Myth of Voter Fraud.” To sway an election, she said, it would require persuading perhaps thousands of people to commit felonies by misrepresenting themselves — and do it undetected.
“It’s ludicrous,” she said. “It’s not an effective way to try to corrupt an election.”
I shouldn't have to say this but, if a story contains claims that the reporter has reason to believe are false or misleading, he or she has an obligation to address the issue promptly. Putting the relevant information above the fold is likely to anger the people who made the false statements, but doing anything else is a disservice to the readers.
Wednesday, March 24, 2021
He came to extend the light of consciousness to the stars and we accused him of having a messiah complex
I am accumulating resources to help make life multiplanetary & extend the light of consciousness to the stars
— Elon Musk (@elonmusk) March 21, 2021
And no, this does not appear to be a joke.
Tuesday, March 23, 2021
There's also a Laffer connection if you follow the links
Cathie Woods predicts Tesla will be worth 300% of the entire auto manufacturing industry within 4 years. They currently have less than 1% market share and lose money selling cars.
— Dean Sheikh (@DeanSheikh1) March 20, 2021
Implies all other car makers will file for bankruptcy.#2021Investing$TSLA
That target has inspired some skepticism.
We are also putting out our new Tesla model and price target. We think you'll find it a little bit more comprehensive and useful than the @ARKInvest model. pic.twitter.com/UOR2Vqx4R8
— ArtkoCapital (@ArtkoCapital) March 21, 2021
That 300% suggests that Tesla will have to find new worlds to conquer. The report lists insurance as a growth opportunity. If you're up for a lesson in how the insurance industry works, this long but dense thread explains why that ain't happening.
FT Alphaville makes many of the same points.I see lots of student company write-ups and pitches. Most are better than yesterday's $3,000 ARK Price Target Report for $TSLA. In reading the report its clear the motivation is to promote a higher stock price. The fantasy involved is simply spectacular... 1/
— Christopher Bloomstran (@ChrisBloomstran) March 20, 2021
Let the pump begin. pic.twitter.com/t3f2CdYHCG
— Keubiko (@Keubiko) March 22, 2021
Woods and many other analysts have done very well embracing Tesla, crypto, and all the other disruptors and their defenders invariably resort to "look at the results" arguments when critics question the projections. With that in mind, let's close with this.
it is logical that at the end of any bull market a team which has embraced the bull (and the bullshit) should be the top perfomers and appear as super heroes.
— John_Hempton (@John_Hempton) March 20, 2021
This is that team.
Monday, March 22, 2021
E.W. Niedermeyer points out an important paradox with autonomous systems -- if Tesla's FSD didn't suck so much, it would be dangerous
The last four seconds of this vid show an egregious and utterly terrifying error for a system that calls itself “Full Self-Driving” https://t.co/B5wJV3dMrU
— Faiz Siddiqui (@faizsays) March 17, 2021
Here's the entire video.
Road and Track has a painful play-by-play.
But E.W. Niedermeyer explains how a pretty good autonomous driving system would actually be more dangerous.
The fact that "Full Self-Driving" is so laughably bad is actually the main reason we haven't had crashes yet. If it improves to the point where it only makes a potentially fatal screwup every 100 miles or more, that's when people will become inattentive and over-trusting. https://t.co/dxh43iI0jX
— E.W. Niedermeyer (@Tweetermeyer) March 17, 2021
Which brings us to the main point from the panel linked above with @missy_cummings, @MikeANees and @mclamann: waiting for mediocre automation to screw up every 10, 50, 100 or 1,000 miles and then making a split-second life-and-death decision is something humans are really bad at!
— E.W. Niedermeyer (@Tweetermeyer) March 19, 2021
For an even more disturbing example, check out this from Jalopnik.
Friday, March 19, 2021
When we said drones will revolutionize the industry, we should have been more specific
Thursday, March 18, 2021
The story is "Tesla has one message for customers and investors, and another one for legal authorities." The meta-story is that the bastion of conventional wisdom is telling this story.
Did you know that Tesla is the first automaker to announce both purchase and subscription options for a product that doesn't exist?
— E.W. Niedermeyer (@Tweetermeyer) March 2, 2021
What is your preferred method of paying for things that aren't even actual things yet? #content
Part 2: These are clips from a 28-minute drive.
— Taylor Ogan (@TaylorOgan) March 16, 2021
There’s a difference between, “The software will get better when the NN has way more data,” vs. hardware ceiled Level 2 ADAS, as even Tesla now admits.
Tesla robotaxi dreamers will have to wait for cars with the proper HW. pic.twitter.com/4RBXCAcNcD
Regardless of where it's reported, this is big news (and potentially grounds for one hell of a class action lawsuit). Still, it's worth noting that highly skeptical coverage of Tesla and Musk is no longer limited to a few voices in the wilderness like Lopez of Business Insider and Hiltzik and Mitchell of the LA Times.
Tesla recently told California regulators that the "Full Self-Driving" beta software it's testing with select customers doesn't make them autonomous — nor will it any time soon.
Why it matters: The company is charging $10,000 extra for the not-really-self-driving, might-arrive-someday addition to its standard Autopilot adaptive cruise-control and lane-keeping feature.
- Meanwhile, CEO Elon Musk is selling investors on the notion that its full self-driving tech will enable Teslas to become money-generating robotaxis.
Our thought bubble: Tesla has one message for customers and investors, and another one for legal authorities.
Catch up quick: Legal transparency website PlainSite this week released a year's worth of correspondence between Tesla lawyers and the California Department of Motor Vehicles, which regulates autonomous vehicles.
- The agency had been pressing Tesla for details about the technology's evolving capability since late 2019 while reminding the company that it does not have a permit to deploy autonomous vehicles in California.
Wednesday, March 17, 2021
I love LA... Penultimate Snow
Last week and this past Monday, the weather included some late winter storms, very probably the last of the year. The snow line got down to twenty-five hundred feet. To put that in perspective, the highest point in the city of LA is just over five thousand feet and highest point in the county is just over over ten.
My standard joke about LA is that we have all the weather you could want; we just drive to it, so this weekend, I headed up the Angeles Crest not far from my place to catch the last snow of the season. Next year, when traveling won't feel so risky, I'll get a cabin and do some hiking. For now, though, these views will have to hold me.
Tuesday, March 16, 2021
Vaccine nuance
This is Joseph.
Are all covid-19 vaccines precisely equal? No. Should you care very much which one you get? Also no. This seems like a contradiction until we think it through.
Prior to the reporting of any phase 3 trials, the pre-specified efficacy for a useful vaccine was often cited as 50%. Here is an NPR story discussing this prior to Pfizer results. It is worth noting, as Bill Miller states, that even a weak vaccine likely reduces severity:
"That's certainly the case with the influenza vaccine," Miller adds. "People who get the vaccine may still get the flu, but, for the most part, their disease is milder than if they hadn't had the vaccine."
So how do the US vaccines stack up to this standard? For the trial endpoints, Pfizer is 95%, Moderna is 94%, and Johnson and Johnson is 72%. Even the lowest efficacy vaccine is almost exactly at the 75% Dr. Fauci pre-specified as what he was hoping for, even if he was unsure it was realistic. Further, there are other trade-offs between the vaccines, including price, storage requirements, or number of doses. The lower efficacy option has better storage properties, is cheaper and is only a single dose. The newer vaccines that might yet be approved also look good, AstraZeneca is 70% and Novavax is 89%, so there are a growing number of options far more effective than the pre-specified level needed for a useful vaccine.
Based on this, there are only safe and effective options available in the United States. I suppose that there might be some customer preferences, but everything is safe and works, based on the trial data.
So what can real world evidence add?
Well, we can try to find rare side effects. There was some concern about the AstraZeneca vaccine (not available in the US) and blood clots, at least until people noticed that the rate was lower than would be expected by chance. One of the sanest voices in the pandemic points out that this might be lower than by chance:
Professor Sir David Spiegelhalter, a statistician from the University of Cambridge, urged caution over the decision to pause the AstraZeneca vaccine rollout in some countries, saying it could be doing "more harm than good".
But it is important to monitor for problems. For example, if there were big ones with the Pfizer vaccine then you'd expect Israel to have noticed by now. Spoiler: there weren't any.
We can also measure the population level effects on disease. So we know that the AstraZeneca (AZ) vaccine appears to reduce population rates of hospitalization by 95%, which was higher than that seen post-vaccination by Pfizer, at 84% (this was based on 1.14 million vaccinations in Scotland) -- although this was mostly comparing single dose Pfizer to single dose AZ (results could differ after 2 doses). Both vaccines are mitigating the human cost of the pandemic, which is the reason the pandemic was a crisis to begin with.
So how does this all link together? All of the evidence suggests all of the vaccines are good. Scotland's real world evidence muddies the waters as to the precise rank ordering (as it is unlikely that the populations being vaccinated were terribly different) but that doesn't change the underlying message: none of the vaccines is showing concerns as to safety or efficacy. I would gladly be randomized to any of the three US available options or to AZ. Even if it was done with a biased die.
Finally, if I did have to do any sort of prioritization then I would do it via focusing on high risk populations. Give the mRNA vaccines to older and minority groups, who suffer more from the disease. Focus the adenovirus vaccines on the young and high SES crowd. That said, vaccines in arms is the most important variable and every person vaccinated does make the community, as a whole, safer.
Looking at Mar 15 data, you would rather be the US (21% with 1+ dose), Israel (57% with 1+ dose), or the UK (37% with 1+ dose) and not somebody like Canada (4.7% with 1+ dose). And the number of doses given is vastly more important than the type of vaccine used, provided it is one of the five above with extensively reported phase three clinical trial data.
Monday, March 15, 2021
If David Wallace-Wells was all that concerned about vaccine hesitancy, maybe he shouldn't have promoted the myth of a West Hollywood autism epidemic
What If Herd Immunity Is Out of Reach? [emphasis added]
A few months ago, these developments might have suggested the true endgame of the pandemic was in sight—and indeed the likely vaccination of 100 million or more by late spring does suggest a dramatic change in the country’s experience of the disease, with those vaccinated feeling safe from hospitalization and death and the disease in retreat. But thanks to a combination of higher herd-immunity estimates, stubbornly high vaccine “hesitancy,” and the arrival of new coronavirus variants that render existing vaccines less effective, the second year of the American pandemic is beginning to look less like a page-turning, book-slammed-shut bang and more like a long and indefinite whimpering into the future — in which many are protected but the disease, undefeated, still circulates, perhaps forever. That the coronavirus would become endemic, like the common cold, has always been one possible outcome, though less appealing than true elimination. The arrival of new variants has made that kind of near-term future, with enduring reservoirs of virus throughout the country, seem less appealing still.
Who do we know with a history of spreading anti-vaxxer talking points?
Tuesday, July 18, 2017
David Wallace-Wells, autism and bad science
David Wallace-Wells has been catching a lot of flack (most of it richly deserved) for his recent New York Magazine article on climate change. It is a hugely troubling sign when the very scientists you were claiming to represent push back against your article.This controversy illustrates a larger problem with science reporting at the magazine. We already have a post in the queue discussing the neutral-to-credulous coverage of topics ranging from homeopathy to magic crystals to Gwyneth Paltrow's goop empire. The Wallace-Wells piece takes things to another level and goes in a very different but arguably worse direction. Rather than giving bad science a pass, he takes good science and presents it so ineptly has to do it a disservice.
I am not going to delve into that science myself. The topic has been well covered by numerous expert and knowledgeable writers [see here and here]. The best I could offer would be a recap. There are some journalistic points I may hit later and I do want to highlight a minor detail in the article that has slipped past most critics, but which is perfectly representative of the dangerous way Wallace-Wells combines sensationalism with a weak grasp of science.
Other stuff in the hotter air is even scarier, with small increases in pollution capable of shortening life spans by ten years. The warmer the planet gets, the more ozone forms, and by mid-century, Americans will likely suffer a 70 percent increase in unhealthy ozone smog, the National Center for Atmospheric Research has projected. By 2090, as many as 2 billion people globally will be breathing air above the WHO “safe” level; one paper last month showed that, among other effects, a pregnant mother’s exposure to ozone raises the child’s risk of autism (as much as tenfold, combined with other environmental factors). Which does make you think again about the autism epidemic in West Hollywood.
No, David, no it doesn't.
I want to be painstakingly careful at this point. These are complex and extraordinarily important issues and it is essential that we do not lose sight of certain basic facts: by any reasonable standard, man-made climate change is one of the two or three most important issues facing our country; the effect of various pollutants on children's mental and physical development should be a major concern for all of us; high ozone levels are a really bad thing.
But the suggestion that ozone levels are causing an autism epidemic in West Hollywood is both dangerous and scientifically illiterate. You'll notice that I did not say that suggesting ozone levels cause autism is irresponsible. Though the study in question is outside of my field, the hypothesis seems reasonable and I do not see any red flags associated with the research. If Wallace-Wells had stopped before adding that last sentence, he would've been on solid ground, but he didn't.
Autism is frightening, mysterious, tragic. This has caused people, particularly parents facing one of the worst moments imaginable, to clean desperately to any explanation that might make sense of their situation. As a result, autism has become a focal point for bad science, culminating with the rise of the anti-vaccination movement. There is no field where groundless speculation and fear-mongering are less welcome.
So, if ozone and other pollutants may contribute to autism, what's so bad about the West Hollywood claim? For that, you need to do some rudimentary causal reasoning, starting with a quick look at ozone pollution in Southern California.
Here are some pertinent facts from a 2015 LA Times article:
EPA Administrator Gina McCarthy selected a limit of 70 parts per billion, which is more stringent than the 75 parts-per-billion standard adopted in 2008 but short of the 60-ppb endorsed by environmentalists and health advocacy groups including the American Lung Assn. The agency’s science advisors had recommended a limit lower than 70 -- and as low as 60.
...
About one-third of California residents live in communities with pollution that exceeds federal standards, according to estimates by the state Air Resources Board.
Air quality is worst in inland valleys, where pollution from vehicles and factories cook in sunlight to form ozone, which is blown and trapped against the mountains.
The South Coast air basin, which includes Los Angeles, Orange, Riverside and San Bernardino counties, violated the current 75-ppb ozone standard on 92 days in 2014. The highest ozone levels in the nation are in San Bernardino County, which reported a 2012-2014 average of 102 parts per billion.
Now let's look at some ozone levels around the region. West Hollywood, it should be noted, is not great.
But just over the Hollywood Hills, the situation is even worse.
Higher still in Riverside ...
Though still far short of what we find in San Bernardino.
If you look at autism rates by school district and compare them to ozone levels, it is difficult to see much of a relationship. Does this mean that ozone does not contribute to autism? Absolutely not. What it shows is that, as with many developmental and learning disabilities, the wealthy are overdiagnosed while poor are underdiagnosed. It is no coincidence that a place like Santa Monica/Maibu (a notorious anti-vaxxer hotspot) has more than double the diagnosis rate of San Bernardino.
The there's this from the very LA Times article by Alan Zarembo that Wallace-Wells cites [emphasis added]:
Irva Hertz-Picciotto, an epidemiologist at UC Davis, suspects that environmental triggers such as exposure to chemicals during pregnancy play a role. In a 2009 study, she started with a tantalizing lead — several autism clusters, mostly in Southern California, that her team had identified from disability and birth records.
But the hot spots could not be linked to chemical plants, waste dumps or any other obvious environmental hazards. Instead, the cases were concentrated in places where parents were highly educated and had easy access to treatment.
Peter Bearman, a sociologist at Columbia University, has demonstrated how such social forces are driving autism rates.
Analyzing state data, he identified a 386-square-mile area centered in West Hollywood that consistently produced three times as many autism cases as would be expected from birth rates.
Affluence helped set the area apart. But delving deeper, Bearman detected a more surprising pattern that existed across the state: Rich or poor, children living near somebody with autism were more likely to have the diagnosis themselves.
Living within 250 meters boosted the chances by 42%, compared to living between 500 and 1,000 meters away.
The reason, his analysis suggested, was simple: People talk.
They talk about how to recognize autism, which doctors to see, how to navigate the bureaucracies to secure services. They talk more if they live next door or visit the same parks, or if their children go to the same preschool.
The influence of neighbors alone accounts for 16% of the growth of autism cases in the state developmental system between 2000 and 2005, Bearman estimated.
In other words, autism is not contagious, but the diagnosis is.
Friday, March 12, 2021
This is getting dumb
This is Joseph
Matt Yglesias commenting on the NYT:
Also noted by Alex Tabbarok:
AZ has on the order of 50 million doses nearly ready to go and can produce in the US around 25 million doses a month so over a year that production is worth over $100 billion to the world economy, far higher than the modest cost of production! Instead of idling this capacity we should expand it even further as part of a plan to vaccinate the world.
I think we need to have a very careful reality check. What could possibly be the reason for not allowing the export of the vaccine? People keep pointing out that Astra-Zeneca has not done the paperwork for an emergency use authorization, but what is the point of letting it sit unused when the company would like to export it.
If it works, why would the United States not want to use it? If it is inferior to current vaccines why should we deny it to countries dealing with large outbreaks? I understand not immediately authorizing it because the US has vaccines with good data already approved but then it should be exportable. I also understand wanting to use it domestically to speed up vaccination rates but then there should be hard questions asked about why the company is not applying to the FDA.
But the current course of action seems to make no actual sense. What am I missing? What is the value in letting the doses expire due to an export ban?